ESMO 2025：基石药业-B(02616.HK)揭晓CS2009(PD-1/VEGF/CTLA-4三特异性抗体)Ⅰ期临床试验数据
CSTONE PHARMACSTONE PHARMA(HK:02616) Ge Long Hui·2025-10-20 00:22

Core Viewpoint - The company announced the presentation of preliminary data from its Phase I clinical study of CS2009 (a tri-specific antibody targeting PD1/VEGF/CTLA-4) and the design of the Phase Ib clinical study for CS5001 (a ROR1 antibody-drug conjugate) at the 2025 European Society for Medical Oncology (ESMO) annual meeting [1] Group 1 - The company is set to present its first clinical research data for CS2009 at a major oncology conference [1] - CS2009 is a tri-specific antibody that targets PD1, VEGF, and CTLA-4, indicating a novel approach in cancer treatment [1] - The design of the Phase Ib clinical study for CS5001 will also be unveiled, showcasing the company's ongoing research efforts in antibody-drug conjugates [1]